Skip to main content

Table 3 Estimated HER2A patient population size based on HER2A prevalence in 5391 non-breast tumors from TCGA

From: HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors

Cancer HER2A percentage Estimated number of new cases in USA, 2015 Estimated number of new HER2A cases
Breast carcinoma 12.3% (106/864) 234190 28805
Stomach adenocarcinoma 8.9% (24/271) 24590 2189
Bladder carcinoma 4.2% (7/168) 74000 3083
Cervical squamous cell carcinoma and uterine carcinosarcoma 4.1% (7/172) 12900 529
Uterine corpus endometrioid carcinoma 3.4% (12/355) 54870 1866
Ovarian serous cystadenocarcinoma 2.7% (11/401) 21290 575
Colon adenocarcinoma 2.5% (5/203) 93090 2327
Lung adenocarcinoma and squamous cell carcinoma 2.4% (21/884) 221200 5309
Head and neck squamous cell carcinoma 2.3% (9/384) 45780 1053
Kidney renal papillary cell carcinoma 1.3% (2/151) N/A N/A
Total across non-BC with HER2 amplification (11 cancers) 3.3% (98/2989)   16931
Total across all non-BC (23 cancers) 1.8% (98/5391)   
  1. Estimate of the number of new, annual human epidermal growth factor receptor 2 (HER2) amplified (HER2A) cancer cases in the USA, based on cancer figures from the American Cancer Society [50] and prevalence of HER2A in The Cancer Genome Atlas (TCGA). BC breast cancer, N/A not available